Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma — Ultime notizie